1 / 7

Particle Size and Polymorph of Drug Substance

Particle Size and Polymorph of Drug Substance. Summary Slides. Polymorph. Screening for Polymorph. Diversity in approaches Focus on DS manufacturing process solvents Investigate beyond solvents in DS manufacturing process and impact on DP process Data should be discussed at the EOP2 meeting

gad
Download Presentation

Particle Size and Polymorph of Drug Substance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Particle Size and Polymorph of Drug Substance Summary Slides

  2. Polymorph

  3. Screening for Polymorph • Diversity in approaches • Focus on DS manufacturing process solvents • Investigate beyond solvents in DS manufacturing process and impact on DP process • Data should be discussed at the EOP2 meeting • Reviewers want assurance of “due diligence”

  4. Polymorph Acceptance Criteria • Qualitative test may be adequate when only one of multiple polymorphs is consistently produced • “Sunset” or “Skip” testing might be an option after demonstration of control • More complicated situations may need bioavailability data to resolve • compare polymorph performance of mixtures and pure forms

  5. Complicated Situations • DS polymorph changes throughout a manufacturing process or during stability • Drug product containing DS with multiple polymorphs having different bioavailabilty

  6. Things to Consider • How close is solution dosage form to saturation solubility for least soluble polymorph • If an amorphous DS is considered for development an EOP2 meeting is important to discuss data. • Decision tree 4 in polymorphism • How different is “different” • “Change” includes DP manufacture and stability

  7. Common Thoughts • Do we need more dialog to enable FDA and industry to understand what is needed to establish tests and acceptance criteria? • Case studies • From joint Industry/Agency group • Is there negative impact from providing additional data and rationale the FDA seems to be asking of Industry?

More Related